Pharmaceutical Resources (PRX)

[mlkrborn]

Par Pharmaceutical (PRX) Acquires Three Generic Products From Teva Pharmaceuticals (TEVA) 39.29 : Co announced that it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. Under terms of the agreement, Par will own the ANDAs of fentanyl citrate lozenges, a generic version of Actiq, and cyclobenzaprine ER capsules, the generic version of Amrix, as well as the U.S. rights to market modafinil tablets, the generic version of Provigil. According to IMS Health data, annual sales in the U.S. for Actiq and the equivalent generic products are $173 mln. Annual sales in the U.S. for Provigil and Amrix are ~$1.1 bln and $125 mln, respectively.